CoChat

Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence

Rodrigues, Nelson B., McIntyre, Roger S., Lipsitz, Orly, Lee, Yena, Cha, Danielle S., Nasri, Flora, Gill, Hartej, Lui, Leanna M.W., Subramaniapillai, Mehala, Kratiuk, Kevin, Lin, Kangguang, Ho, Roger, Mansur, Rodrigo B., Rosenblat, Joshua D. · 2020 · Expert Opinion on Drug Safety
Cited by 51

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

OBJECTIVES: Rigorous clinical trials suggest ketamine is safe and well-tolerated in patients with treatment-resistant depression (TRD). There is a paucity of data on the safety and tolerability of ketamine in community-based clinics treating patients with TRD. METHODS: Retrospective data was analyzed from 203 patients with TRD who received repeat-dose IV ketamine. Safety was operationalized as hemodynamic changes. Tolerability was evaluated through the reporting of adverse events and dissociation symptom severity, as measured by the Clinician-Administered Dissociative States Scale. RESULTS: Ketamine was well-tolerated, with less than 5% of patients withdrawing due to tolerability concerns. Blood pressure significantly increased during infusion, with 44.3% meeting criteria for treatment-emergent hypertension (i.e., blood pressure ≥ 165/100 mmHg). 12% of patients exhibiting hypertension required pharmacological intervention. The most frequently reported adverse events included drowsiness (56.4%), dizziness (45.2%), dissociation (35.6%), and nausea (13.3%). Dissociation severity significantly attenuated after the first infusion, but plateaued for subsequent infusions. CONCLUSION: Intravenous ketamine was safe and well-tolerated. Hypertension was commonly observed and was often transient. Dissociation was most frequently reported after the first infusion but remained a consistent but not treatment-limiting adverse event thereafter. No patients exhibited psychosis, mania, or new onset suicidality with IV ketamine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/14740338.2020.1776699

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 51

Metadata

Authors
Rodrigues, N. B., McIntyre, R. S., Lipsitz, O., Lee, Y., Cha, D. S., Nasri, F., Gill, H., Lui, L. M. W., Subramaniapillai, M., Kratiuk, K., Lin, K., Ho, R., Mansur, R. B., & Rosenblat, J. D.
Venue
Expert Opinion on Drug Safety
Published
2020-06-15
Volume
19
Issue
8
Pages
1031-1040
ISSN
  • 1474-0338 (ISSN-L)
  • 1744-764X
OpenAlex
W3034357715
Cited by
51
References
22
FWCI
3.53
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence. https://app.cochat.ai/papers/10.1080/14740338.2020.1776699
The paper
Rodrigues, N. B., McIntyre, R. S., Lipsitz, O., Lee, Y., Cha, D. S., Nasri, F., Gill, H., Lui, L. M. W., Subramaniapillai, M., Kratiuk, K., Lin, K., Ho, R., Mansur, R. B., & Rosenblat, J. D. (2020). Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2020.1776699

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.